These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 18024667)
21. RNAi therapy for neurodegenerative diseases. Boudreau RL; Davidson BL Curr Top Dev Biol; 2006; 75():73-92. PubMed ID: 16984810 [TBL] [Abstract][Full Text] [Related]
22. Therapeutic potential of adenoviral vectors for delivery of expressed RNAi activators. Mowa MB; Crowther C; Arbuthnot P Expert Opin Drug Deliv; 2010 Dec; 7(12):1373-85. PubMed ID: 21073358 [TBL] [Abstract][Full Text] [Related]
23. RNA interference-mediated virus clearance from cells both acutely and chronically infected with the prototypic arenavirus lymphocytic choriomeningitis virus. Sánchez AB; Perez M; Cornu T; de la Torre JC J Virol; 2005 Sep; 79(17):11071-81. PubMed ID: 16103158 [TBL] [Abstract][Full Text] [Related]
24. Development of resistance to RNAi in mammalian cells. Zheng ZM; Tang S; Tao M Ann N Y Acad Sci; 2005 Nov; 1058():105-18. PubMed ID: 16394130 [TBL] [Abstract][Full Text] [Related]
25. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials. DeVincenzo JP Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462 [TBL] [Abstract][Full Text] [Related]
26. RNAi applications in therapy development for neurodegenerative disease. Maxwell MM Curr Pharm Des; 2009; 15(34):3977-91. PubMed ID: 19751205 [TBL] [Abstract][Full Text] [Related]
28. Optimal delivery of RNA interference by viral vectors for cancer therapy. Wong B; Birtch R; Rezaei R; Jamieson T; Crupi MJF; Diallo JS; Ilkow CS Mol Ther; 2023 Nov; 31(11):3127-3145. PubMed ID: 37735876 [TBL] [Abstract][Full Text] [Related]
29. RNA interference and its current application in mammals. Shen WG Chin Med J (Engl); 2004 Jul; 117(7):1084-91. PubMed ID: 15265387 [TBL] [Abstract][Full Text] [Related]
30. Genome-wide application of RNAi to the discovery of potential drug targets. Ito M; Kawano K; Miyagishi M; Taira K FEBS Lett; 2005 Oct; 579(26):5988-95. PubMed ID: 16153642 [TBL] [Abstract][Full Text] [Related]
31. Rapid and stable knockdown of an endogenous gene in retinal pigment epithelium. Paskowitz DM; Greenberg KP; Yasumura D; Grimm D; Yang H; Duncan JL; Kay MA; Lavail MM; Flannery JG; Vollrath D Hum Gene Ther; 2007 Oct; 18(10):871-80. PubMed ID: 17892416 [TBL] [Abstract][Full Text] [Related]
32. Lentiviral delivery of RNAi in hippocampal neurons. Janas J; Skowronski J; Van Aelst L Methods Enzymol; 2006; 406():593-605. PubMed ID: 16472690 [TBL] [Abstract][Full Text] [Related]
33. CRISPR genome engineering and viral gene delivery: a case of mutual attraction. Schmidt F; Grimm D Biotechnol J; 2015 Feb; 10(2):258-72. PubMed ID: 25663455 [TBL] [Abstract][Full Text] [Related]
34. Transkingdom RNA interference (tkRNAi) as a new delivery tool for therapeutic RNA. Aigner A Expert Opin Biol Ther; 2009 Dec; 9(12):1533-42. PubMed ID: 19769540 [TBL] [Abstract][Full Text] [Related]
35. RNA interference in functional genomics and medicine. Kim VN J Korean Med Sci; 2003 Jun; 18(3):309-18. PubMed ID: 12808314 [TBL] [Abstract][Full Text] [Related]
36. [Application of RNAi library to oncology investigation]. Weng DH; Wang SX; Ma D Ai Zheng; 2008 Nov; 27(11):1229-32. PubMed ID: 19000460 [TBL] [Abstract][Full Text] [Related]
39. Combinatorial RNAi: a winning strategy for the race against evolving targets? Grimm D; Kay MA Mol Ther; 2007 May; 15(5):878-88. PubMed ID: 17311009 [TBL] [Abstract][Full Text] [Related]
40. Therapeutic application of RNA interference for hepatitis C virus. Watanabe T; Umehara T; Kohara M Adv Drug Deliv Rev; 2007 Oct; 59(12):1263-76. PubMed ID: 17822803 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]